Skeletal muscle loss during chemotherapy and its association with survival and systemic treatment toxicity in metastatic colorectal cancer: An AGEO prospective multicenter study

Gallois, Claire; Bourillon, Camille; Auclin, Édouard; Artru, Pascal; Lièvre, Astrid; Lecomte, Thierry; Locher, Christophe; Faroux, Roger; Pernot, Simon; Barret, Maximilien; Taı̈eb, Julien

doi:10.1016/j.clinre.2020.101603

Cited by 13 publications

(30 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most of the included studies used the well-established cut-off values proposed by Martin et al and by Prado et al 1 , 12 There might be small differences regarding cm ²/m ² for women compared to Martin et al 1 , 12 Some studies did not use a similar, established approach, such as Gallois et al, which employed an internal cut-off value derived by the lowest sex specific quartile identified in the study. 20 In the study by Horii et al, the exact definition of LSMM is not even mentioned by the authors, which could lead to a possible bias and reduces possible reproduction of their results. 22 One can postulated that the cut-off values by Martin et al 12 , and Prado et al 1 are most commonly used in the literature and they can be considered as evident thresholds.…”

Section: Discussionmentioning

confidence: 97%

“…After thorough review, 15 studies were suitable for the analysis and included into the present study. [15][16][17][18][19][20][21][22][23][24][25][26][27][28][29] The primary aim of the systematic review was to investigate the influence of LSMM on OS by means of the effect measure hazard ratio. Moreover, the frequency of sarcopenia was assessed in the analyzed studies.…”

Section: Inclusion Criteriamentioning

confidence: 99%

“…19 Furthermore, 1 study used a sex-specific cut-off value based on the lowest quartile. 20 Also 1 study used the values ≤31 cm ²/m ² for women and below or equal to 49 cm ²/m ² for men. 21 One study used a Hounsfield unit threshold of below 22 HU.…”

Section: Measurement Of Lsmmmentioning

confidence: 99%

See 2 more Smart Citations

Prognostic Role of Low-Skeletal Muscle Mass on Staging Computed Tomography in Metastasized Colorectal Cancer: A Systematic Review and Meta-Analysis

Meyer¹,

Strobel²,

Wienke³

et al. 2022

Clinical Colorectal Cancer

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 97%

Section: Inclusion Criteriamentioning

confidence: 99%

See 1 more Smart Citation

Prognostic Role of Low-Skeletal Muscle Mass on Staging Computed Tomography in Metastasized Colorectal Cancer: A Systematic Review and Meta-Analysis

Meyer¹,

Strobel²,

Wienke³

et al. 2022

Clinical Colorectal Cancer

View full text Add to dashboard Cite

“…Progressive muscle wasting may be a stronger prognostic factor than a single pre-treatment measurement. In a recent study in patients with metastatic CRC, continuing muscle loss but not pre-treatment sarcopenia was prognostic of worse OS [25].…”

Section: Discussionmentioning

confidence: 91%

Association between postoperative muscle wasting and survival in older patients undergoing surgery for non-metastatic colorectal cancer

Argillander¹,

Spek²,

Zaag-Loonen³

et al. 2021

Journal of Geriatric Oncology

View full text Add to dashboard Cite

Background: Preoperative sarcopenia in older patients is a risk factor for adverse outcomes after colorectal cancer (CRC) surgery. Longitudinal changes in muscle mass in this group have not been studied previously although muscle wasting may have prognostic significance regarding survival. We aimed to determine the association between muscle wasting and overall survival (OS) in older patients who underwent surgery for CRC. Methods: Patients ≥70 years who underwent surgery for non-metastatic CRC in Gelre hospitals, The Netherlands, between 2011 and 2015 were included. Cross-sectional area of skeletal muscle was measured at the level of the 3rd lumbar vertebra on preoperative and postoperative abdominal CT-scans. Patients who had >1 standard deviation decrease in muscle mass were considered to have muscle wasting. Cox regression analysis was used to evaluate associations between muscle wasting and OS. Results: 233 patients were included (40% female, median age 76 years). Thirty-four patients had muscle wasting. After a median follow-up of 4.7 years, 53 (23%) patients died. The 3-year mortality rate was higher in patients with muscle wasting (27% vs 14%, p = .05). In multivariable analysis adjusted for age, recurrent disease and preoperative muscle mass, muscle wasting was associated with reduced OS (HR 2.8, 95% CI 1.5-5.4, p = .002). Conclusion:Muscle wasting predicted poorer survival in older patients who underwent CRC surgery. Measuring changes in muscle mass may improve risk prediction in this patient group. Future studies should address the etiology of muscle wasting in older patients with CRC. Whether perioperative exercise interventions can prevent muscle wasting also warrants further study.

show abstract

“…Table 1 presents the baseline characteristics of the included studies. Among the studies published between 20 16 and 2022, 8 studies [ 27 – 29 , 37 , 40 , 42 , 45 , 46 ] were from Asia, 7 studies [ 39 , 41 , 43 , 44 , 47 – 49 ] were from Europe and a separate study [ 38 ] from Brazil. All of the studies were retrospective cohort, and 68.75% of the included studies (11/16) were of high quality with an NOS score of ≥ 7).…”

Section: Resultsmentioning

confidence: 99%

Sarcopenia as a risk factor of progression-free survival in patients with metastases: a systematic review and meta-analysis

et al. 2023

View full text Add to dashboard Cite

Background Metastasis of cancer causes more than 90% of cancer deaths and is severely damaging to human health. In recent years, several studies have linked sarcopenia to shorter survival in patients with metastatic cancer. Several predictive models exist to predict mortality in patients with metastatic cancer, but have reported limited accuracy. Methods We systematically searched Medline, EMBASE, and the Cochrane Library for articles published on or before October 14, 2022. Pooled Hazard Ratio (HR) estimates with 95% confidence intervals (CIs) were calculated using a random effects model. The primary outcome was an increased risk of death or tumor progression in patients with metastatic cancer, which is expressed as progression-free survival (PFS). In addition, we performed subgroup analyses and leave-one-out sensitivity analyses to explore the main sources of heterogeneity and the stability of the results. Results Sixteen retrospective cohort studies with 1,675 patients were included in the 888 papers screened. The results showed that sarcopenia was associated with lower progression-free survival (HR = 1.56, 95% CI = 1.19–2.03, I2 = 76.3%, P < 0.001). This result was further confirmed by trim-and-fill procedures and leave-one-out sensitivity analysis. Conclusions This study suggests that sarcopenia may be a risk factor for reduced progression-free survival in patients with metastatic cancer. Further studies are still needed to explain the reason for this high heterogeneity in outcome. Trial registration CRD42022325910.

show abstract

Skeletal muscle loss during chemotherapy and its association with survival and systemic treatment toxicity in metastatic colorectal cancer: An AGEO prospective multicenter study

Cited by 13 publications

References 20 publications

Prognostic Role of Low-Skeletal Muscle Mass on Staging Computed Tomography in Metastasized Colorectal Cancer: A Systematic Review and Meta-Analysis

Prognostic Role of Low-Skeletal Muscle Mass on Staging Computed Tomography in Metastasized Colorectal Cancer: A Systematic Review and Meta-Analysis

Association between postoperative muscle wasting and survival in older patients undergoing surgery for non-metastatic colorectal cancer

Sarcopenia as a risk factor of progression-free survival in patients with metastases: a systematic review and meta-analysis

Contact Info

Product

Resources

About